Article
A Genotype-Guided Strategy for Oral P2Y 12 Inhibitors in Primary PCI
3 Sept 2019
Abstract excerpt
BACKGROUND: inhibitors. METHODS: *3 loss-of-function alleles received ticagrelor or prasugrel, and noncarriers received clopidogrel. The two primary outcomes were net adverse clinical events - defined as death from any cause, myocardial infarction, definite stent thrombosis, stroke, or major bleeding defined according to Platelet Inhibition and Patient Outcomes (PLATO) criteria - at 12 months (primary combined...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.